Conclusions
SARS-Cov-2 has highlighted even more the serious safety problems of
drugs for MS especially with regard to new immunomodulatory drugs with
increased potential risks of infection. Is it safe to continue therapy
during the pandemic? Based on the evidence in the literature, the
position of the agencies in the different countries and given the
complexity of the treatment of MS the best thing is that the decision is
based on the individual condition of the patient. It is useless to hide
that the therapy must be even more personalized and the patient
carefully monitored. MS needs to be treated avoiding infection risks:
the doctor’s job is to maintain this balance by ensuring the greatest
possible safety. Depletive therapies, which significantly affect the
patient’s immune system, safely lead to a decrease in lymphocytes and an
associated risk of infection. However, failure to take therapies can
lead the patient to have new disease attacks and for this there is no
reason to stop without proven need. It is important to follow national
and international guidelines and the positions of scientific societies
and regulatory agencies because the therapy must be personalized as much
as possible according to the clinical picture. Important for this is
constant monitoring.